Shares of VCA Inc. (NASDAQ:WOOF) gapped up prior to trading on Wednesday . The stock had previously closed at $68.43, but opened at $68.50. VCA shares last traded at $69.22, with a volume of 412,931 shares.

A number of analysts recently commented on WOOF shares. Jefferies Group started coverage on VCA in a research note on Wednesday, June 8th. They issued a “hold” rating for the company. Stifel Nicolaus raised their price target on VCA from $68.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, April 28th. CL King started coverage on VCA in a research note on Friday, April 1st. They issued a “buy” rating for the company. Finally, Zacks Investment Research lowered VCA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $65.00.

The stock has a market capitalization of $5.58 billion and a price-to-earnings ratio of 25.83. The stock has a 50-day moving average price of $66.62 and a 200-day moving average price of $58.73.

VCA (NASDAQ:WOOF) last posted its earnings results on Wednesday, April 27th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.05. The business had revenue of $563.40 million for the quarter, compared to analyst estimates of $556.03 million. During the same period last year, the business earned $0.50 EPS. VCA’s revenue was up 12.8% compared to the same quarter last year. Analysts forecast that VCA Inc. will post $2.87 EPS for the current year.

In other news, COO Arthur J. Antin sold 200,000 shares of VCA stock in a transaction on Wednesday, May 18th. The stock was sold at an average price of $64.04, for a total value of $12,808,000.00. Following the completion of the sale, the chief operating officer now directly owns 70,870 shares of the company’s stock, valued at $4,538,514.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Josh Drake sold 2,091 shares of VCA stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $66.05, for a total value of $138,110.55. Following the completion of the sale, the insider now directly owns 59,698 shares of the company’s stock, valued at $3,943,052.90. The disclosure for this sale can be found here.

Several large investors have recently modified their holdings of the stock. American Capital Management Inc. boosted its stake in shares of VCA by 3.5% in the fourth quarter. American Capital Management Inc. now owns 20,800 shares of the company’s stock worth $1,144,000 after buying an additional 700 shares during the last quarter. US Bancorp DE boosted its stake in shares of VCA by 16.6% in the fourth quarter. US Bancorp DE now owns 30,684 shares of the company’s stock worth $1,687,000 after buying an additional 4,369 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of VCA by 2.1% in the fourth quarter. Principal Financial Group Inc. now owns 260,395 shares of the company’s stock worth $14,322,000 after buying an additional 5,275 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of VCA by 2.5% in the fourth quarter. California Public Employees Retirement System now owns 257,300 shares of the company’s stock worth $14,152,000 after buying an additional 6,200 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of VCA by 5.0% in the fourth quarter. New York State Common Retirement Fund now owns 224,696 shares of the company’s stock worth $12,358,000 after buying an additional 10,746 shares during the last quarter.

VCA Inc is an animal healthcare company. The Company operates through five segments. Its Animal Hospital segment provides veterinary services for companion animals and sells related retail and pharmaceutical products. Its Laboratory segment provides diagnostic laboratory testing services for veterinarians, both associated with its animal hospitals and those independent of the Company.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.